We are live on
!
Find out more
Immunic
IMUX
IMUX
75 hedge funds and large institutions have $78.5M invested in Immunic in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
549% more call options, than puts
Call options by funds: $526K | Put options by funds: $81K
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
178% more capital invested
Capital invested by funds: $28.3M → $78.5M (+$50.2M)
129% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 14
29% more funds holding
Funds holding: 58 → 75 (+17)
0.77% more ownership
Funds ownership: 4.26% → 5.03% (+0.77%)
Holders
75
Holders Change
+17
Holders Change %
+29.31%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
20
Reduced
7
Closed
14
Calls
$526K
Puts
$81K
Net Calls
+$445K
Net Calls Change
+$211K
Top Buyers
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.03M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$2.39M |
| 3 |
6CM
683 Capital Management
New York
|
+$2.19M |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$2.1M |
| 5 |
Morgan Stanley
New York
|
+$1.07M |
